Video

Dr. Mato on Immunotherapy Options in CLL

Anthony R. Mato, MD, MSCE, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia (CLL).

Allogeneic stem cell transplantation is one type of immunotherapy that has shown benefit in CLL, says Mato. CD20-targeted monoclonal antibodies are also immune agonists that are approved in CLL, Mato explains.

Additional immunotherapy strategies are still investigational. Though, CAR T-cell therapy, immune checkpoint inhibitors, and bispecific antibodies are beginning to emerge, says Mato. Mato believes these options will continue to gain traction in the field given their potential to provide long-term disease control.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Ami Umesh Badami, MD
Premal Thaker, MD, MS
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.